Takeda Pharmaceutical Files June 2024 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jun 3, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Takeda filed its June 6-K, confirming 20-F annual report status. All good.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on June 3, 2024, reporting information for the month of June 2024. The filing indicates Takeda is a foreign private issuer and will file its annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.
Why It Matters
This filing serves as an update for investors regarding Takeda's regulatory reporting status as a foreign private issuer. It confirms their adherence to SEC filing requirements.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming reporting status and is not indicative of any specific company risks.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- 001-38757 (company) — SEC File Number
- 20240603 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the registrant filing this report?
The registrant is Takeda Pharmaceutical Company Limited.
When was this report filed?
The report was filed on June 3, 2024.
What is Takeda's principal executive office location?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Under which form will Takeda file its annual reports?
Takeda will file its annual reports under cover of Form 20-F.
Filing Stats: 743 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-06-03 06:26:56
Filing Documents
- form6k-1_060324.htm (6-K) — 25KB
- 0001395064-24-000058.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date June 3, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan Osaka, Japan, June 3, 2024 -- Takeda Pharmaceutical Company Limited ("Company") announced today that after the Company withdraws the Shelf Registration Statement regarding the issuance of new shares filed on June 1, 2023, it will file a Shelf Registration Statement in Japan regarding the issuance of new shares or disposition of treasury shares. The purpose of the filing is to issue new shares of common stock or dispose treasury shares in a timely and flexible manner in association with the continued implementation of a Long Term Incentive Plan ("LTIP"). For details of the LTIP, please refer to "Launch of a New Employee Stock Purchase Plan and Long Term Incentive Plan for Company Group Employees Overseas" released on June 24, 2020. 1. Purpose of Shelf Registration Please see above. 2. Class of Securities to be Offered Shares of common stock of the Company 3. Scheduled Issue Period For the period from the scheduled effective date of the Shelf Registration to the date that is one year after such scheduled effective date (currently scheduled from June 11, 2024 to June 10, 2025) 4. Scheduled Issue Amount Up to JPY 220 billion 5. Use of Proceeds The issuance of new shares of common stock or disposition of treasury shares related to the Shelf Registration will be conducted based on the LTIP and is not intended to raise funds. 6. Terms of Offering To be determined. The scheduled issue amount above is the estimated maximum total of both (1) the number of LTIP units that will vest and (2) th